Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, Huntsman Cancer Institute, discusses the safety profile of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Researchers did not observe any new safety signals with the combination in the phase Ib COSMIC-021 study, says Agarwal. Most of the adverse events (AEs) reported with the combination were grade 1 and 2, adds Agarwal; however, treatment-related AEs occurred in 59% of patients. Among the most commonly reported grade 3 events were fatigue, diarrhea, and hyponatremia. It’s important to note that the patient population of this study is much older than many other patient populations with other kinds of cancers, says Agarwal.
The combination showed very exciting objective responses, disease control rate, duration of responses, and high tolerability, which makes it very promising, says Agarwal. Hopefully, these patients will have the option of continuing to the phase III trial, which will be activating soon and will be available across the United States and the globe, concludes Agarwal.